Alzheimer’s Drugs Market Report 2021 : Industry Insights, Estimated Yield, Recent Developments and Forecast to 2027 with Dominant Regions and Countries Data

Increasing prevalence of Alzheimer’s disease is fueling the demand for Alzheimer’s drugs which in turn is driving the global Alzheimer’s drugs market, says Fortune Business Insights in a report, titled “Alzheimer’s Drugs Market”, Size, Share and Global Trend By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Antagonist, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2026.

Rising R&D activities by pharmaceutical companies and research institutes for Alzheimer effective therapy is expected to boost the global Alzheimer’s drugs market.

Request a Sample Copy of the Research Report:

The Collaboration Between Eli Lilly and AC Immune Will Aid Growth 

Eli Lilly and Company and AC Immune SA announced their partnership agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The collaboration between the two companies is predicted to benefit Alzheimer’s drugs revenue owing to the Morphomer™ platform technology which will offer commercial capabilities in central nervous system disorders along with AC Immune’s lead molecule, ACI-3024. Furthermore, the development of digital tools for Alzheimer’s disease and dementia is also expected to contribute to the global Alzheimer’s drugs growth. For instance, the Alzheimer’s Drug Discovery Foundation (ADDF), announced a new initiative -Diagnostics Accelerator program that aims to track the development of digital tools for Alzheimer’s disease and dementia.

Increasing R&D Investments by Pharmaceutical Companies Will Propel Growth 

The active study of Alzheimer’s drug by pharmaceutical industries and research institutes for creating a strong pipeline for effective therapy is predicted to encourage growth of the global Alzheimer’s drugs market. According to the World Health Organization (WHO) currently, 50 million people are affected by dementia, and the number is expected to increase during the forecast period. In addition, the increasing cases of Alzheimer’s disease around the world have led towards high demand for Alzheimer’s drugs, which in turn is boosting the global Alzheimer’s drugs growth. However, discontinuation of clinical trials for Alzheimer’s drugs by leading pharmaceutical companies which is resulting in limited treatment options and thus creating a global economic burden by increasing the nation’s annual treatment cost against Alzheimer’s drugs development and disease treatment. This factor is predicted to hamper the growth of the global Alzheimer’s drugs market during the forecast period. For instance, Eisai and Biogen, Co., Ltd., declared the termination of phase 3 clinical trial of ENGAGE and EMERGE designed to evaluate the safety and efficacy in the treatment of Alzheimer’s disease.

Leading Players operating in the Alzheimer’s Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Hoffmann-La Roche Ltd,
  • Novartis AG,
  • Pfizer Inc.,
  • Eli Lilly and Company.,
  • Merck Sharp & Dohme Corp.,
  • AstraZeneca,
  • Biogen,
  • AbbVie Inc.,
  • other players

Have Any Query? Ask Our Experts:

Increasing Prevalence of Alzheimer’s Disease Will Boost Growth in North America

Geographically, the global Alzheimer’s drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The global Alzheimer’s drugs market is predicted to expand in North America during the forecast period owing to the rising cases of Alzheimer’s disease and the presence of key players in the region. According to Alzheimer’s Association, currently, 5.8 million Americans are living with Alzheimer’s, and the number is expected to increase to 14 million by 2050, which is expected to promote the growth of the Alzheimer’s drugs market in North America. Europe is predicted to grow significantly during the forecast period owing to the increasing prevalence of Alzheimer’s disease. Improving diagnostic capabilities are also expected to boost the market in the region. Evolving healthcare infrastructure and rising awareness regarding Alzheimer’s disease are expected to contribute significantly to Alzheimer’s drugs growth in Asia Pacific and Latin America. Additionally, Alzheimer’s drugs market in Middle East & Africa is in the nascent stage; however, unmet needs for Alzheimer’s disease is expected to drive the Alzheimer’s drugs market in this region.

Get your Customized Research Report:

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:[email protected]

Linkedin | Twitter | BLogs

Leave a Reply

Your email address will not be published. Required fields are marked *